PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmcgeneBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Genetics
 
BMC Genet. 2001; 2: 9.
Published online Jun 29, 2001. doi:  10.1186/1471-2156-2-9
PMCID: PMC35353
A missense mutation (Q279R) in the Fumarylacetoacetate Hydrolase gene, responsible for hereditary tyrosinemia, acts as a splicing mutation
Natacha Dreumont,1 Jacques A Poudrier,1 Anne Bergeron,1 Harvey L Levy,2 Faouzi Baklouti,3 and Robert M Tanguaycorresponding author1
1 Laboratory of Cellular and Developmental Genetics, Dept Medicine, Pavillon Marchand, Université Laval, and Centre de Recherche du CHUQ (Pav CHUL), Ste-Foy, Québec, Canada
2 Div Genetics, Children's Hospital, and Dept Pediatrics, Harvard Medical School, Boston, Mass 02115, USA
3 CNRS UMR 5534, Centre de Génétique Moléculaire et Cellulaire, Université Lyon 1, Villeurbanne 69622, France
corresponding authorCorresponding author.
Natacha Dreumont: labrt/at/rsvs.ulaval.ca; Jacques A Poudrier: poudrier/at/iigbna.iigb.na.cnr.it; Anne Bergeron: abh965/at/agora.ulaval.ca; Harvey L Levy: LEVY_H/at/AI.TCH.HARVARD.EDU; Faouzi Baklouti: Faouzi.Baklouti/at/univ-lyon1.fr; Robert M Tanguay: Robert.Tanguay/at/rsvs.ulaval.ca
Received May 5, 2001; Accepted June 29, 2001.
Abstract
Background
Tyrosinemia type I, the most severe disease of the tyrosine catabolic pathway is caused by a deficiency in fumarylacetoacetate hydrolase (FAH). A patient showing few of the symptoms associated with the disease, was found to be a compound heterozygote for a splice mutation, IVS6-1g->t, and a putative missense mutation, Q279R. Analysis of FAH expression in liver sections obtained after resection for hepatocellular carcinoma revealed a mosaic pattern of expression. No FAH was found in tumor regions while a healthy region contained enzyme-expressing nodules.
Results
Analysis of DNA from a FAH expressing region showed that the expression of the protein was due to correction of the Q279R mutation. RT-PCR was used to assess if Q279R RNA was produced in the liver cells and in fibroblasts from the patient. Normal mRNA was found in the liver region where the mutation had reverted while splicing intermediates were found in non-expressing regions suggesting that the Q279R mutation acted as a splicing mutation in vivo. Sequence of transcripts showed skipping of exon 8 alone or together with exon 9. Using minigenes in transfection assays, the Q279R mutation was shown to induce skipping of exon 9 when placed in a constitutive splicing environment.
Conclusion
These data suggest that the putative missense mutation Q279R in the FAH gene acts as a splicing mutation in vivo. Moreover FAH expression can be partially restored in certain liver cells as a result of a reversion of the Q279R mutation and expansion of the corrected cells.
Articles from BMC Genetics are provided here courtesy of
BioMed Central